Adamax
Next-Generation Semax Derivative | Nootropic Neuropeptide
Adamax is a synthetic nootropic peptide and enhanced derivative of Semax, featuring N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration. It's researched for cognitive enhancement, neuroprotection, neuroplasticity, and potential therapeutic applications in stroke recovery and mood disorders.
Daily dose
200-300mcg
Frequency
1x daily
Cycle length
2-4 weeks
Storage
2-8°C
Key benefits
Enhanced cognitive function, improved focus and mental clarity, neuroprotection, neuroplasticity support, mood enhancement, and stress resilience. Superior stability and blood-brain barrier penetration compared to parent compound Semax.
How it works
Adamax crosses the blood-brain barrier via enhanced lipophilicity from adamantane modification. It upregulates BDNF and TrkB receptor sensitivity in hippocampus, modulates key neurotransmitters (dopamine, norepinephrine, serotonin), stabilizes microtubules through ADNP-derived mechanisms, and provides antioxidant and anti-inflammatory neuroprotection.
Dosage protocols
Goal
Cognitive enhancement
Dose
200-300mcg · 1x daily
Route
SubQ or intranasal
Goal
Neuroprotection
Dose
300mcg · 1-2x daily
Route
SubQ
Goal
Mood support
Dose
200mcg · 1x daily (morning)
Route
SubQ or oral
Goal
Initial trial
Dose
100-200mcg · 1x daily
Route
SubQ
Research indications
cognitive
neuroprotective
mood
Administration
Interactions
Safety notes
CRITICAL: Experimental peptide with very limited human research data
Use sterile injection technique
Start with lower doses to assess tolerance
Monitor for cardiovascular effects (blood pressure, palpitations)
Cycle with breaks to prevent tolerance
Not recommended during pregnancy or breastfeeding
Consult healthcare provider before use
Research studies
Adamax Stroke Recovery Preliminary Reports
Humans | Dosage not specified | Variable administration | Observational
Preliminary clinical observations indicate patients treated with Adamax shortly after stroke had better neurological outcomes compared to control groups, potentially through reduction of oxidative stress and neuronal repair mechanisms.
View study →BDNF and TrkB Receptor Upregulation Studies
In vitro and animal models | Various concentrations | BDNF expression measured
Research demonstrates Adamax increases Brain-Derived Neurotrophic Factor (BDNF) levels and enhances TrkB receptor sensitivity in the hippocampus, fundamental mechanisms for neuroplasticity and cognitive enhancement.
View study →Neurotransmitter Modulation in Cognitive Enhancement
Animal models | Various doses | Neurotransmitter levels measured
Research indicates Adamax influences levels of dopamine, norepinephrine, and serotonin, contributing to improved mood, reduced anxiety, and enhanced cognitive function through balanced neurotransmitter activity.
View study →Microtubule Assembly and Stability Research (ADNP Connection)
Cellular studies | ADNP-derived mechanisms | Microtubule protein binding
Studies show Adamax, derived from ADNP principles, binds to microtubule end-binding proteins and promotes microtubule assembly, stability, and transport - critical for neuronal structure and function.
View study →Semax in Stroke Recovery - BDNF Elevation (Parent Compound)
Humans | 110 patients | 6000 mcg/day intranasal | Two 10-day courses
Parent compound Semax trial in stroke patients showed increased plasma BDNF levels, improved motor performance and enhanced functional independence. Adamax's enhanced stability suggests potential for superior neuroprotective effects.
View study →Semax Cognitive Enhancement in Fatigued Volunteers (Parent Compound)
Humans | 16 mcg/kg intranasal | Single dose | 24-hour effects
Study on parent compound Semax showed single intranasal administration resulted in 71% accuracy rate on memory tests versus 41% in controls, with effects lasting 24 hours. Adamax is theorized to provide enhanced effects due to structural modifications.
View study →